Relationship Between Genotype Status and Clinical Outcome in Hypertrophic Cardiomyopathy

Bonaventura, Jiří; Rowin, Ethan J.; Chan, Raymond H.; Chin, Michael T.; Puchnerová, VeronikaPolaková, Eva; Macek, Milan; Votýpka, Pavel; Batorsky, Rebecca; Perera, Gayani; Koethe, Benjamin; Veselka, Josef; Maron, Barry J.; Maron, Martin S. Journal of the American Heart Association. May 2024. IF: 6,1. doi.

MUDr. Jiří Bonaventura, Ph. D. Department of Cardiology, Second Faculty od Medicine and Motol University Hospital

MUDr. Jiří Bonaventura, Ph. D., Department of Cardiology, Second Faculty od Medicine and Motol University Hospital

Abstract

Background: The genetic basis of hypertrophic cardiomyopathy (HCM) is complex, and the relationship between genotype status and clinical outcome is incompletely resolved.

Methods and results: We assessed a large international HCM cohort to define in contemporary terms natural history and clinical consequences of genotype. Consecutive patients (n=1468) with established HCM diagnosis underwent genetic testing. Patients with pathogenic (or likely pathogenic) variants were considered genotype positive (G+; n=312; 21%); those without definite disease-causing mutations (n=651; 44%) or variants of uncertain significance (n=505; 35%) were considered genotype negative (G-). Patients were followed up for a median of 7.8 years (interquartile range, 3.5-13.4 years); HCM end points were examined by cumulative event incidence. Over follow-up, 135 (9%) patients died, 33 from a variety of HCM-related causes. After adjusting for age, all-cause and HCM-related mortality did not differ between G- versus G+ patients (hazard ratio [HR], 0.78 [95% CI, 0.46-1.31]; P=0.37; HR, 0.93 [95% CI, 0.38-2.30]; P=0.87, respectively). Adverse event rates, including heart failure progression to class III/IV, heart transplant, or heart failure death, did not differ (G- versus G+) when adjusted for age (HR, 1.20 [95% CI, 0.63-2.26]; P=0.58), nor was genotype independently associated with sudden death event risk (HR, 1.39 [95% CI, 0.88-2.21]; P=0.16). In multivariable analysis, age was the only independent predictor of all-cause and HCM-related mortality, heart failure progression, and sudden death events.

Conclusions: In this large consecutive cohort of patients with HCM, genotype (G+ or G-) was not a predictor of clinical course, including all-cause and HCM-related mortality and risk for heart failure progression or sudden death. G+ status should not be used to dictate clinical management or predict outcome in HCM.

Keywords: genotype; hypertrophic cardiomyopathy; mortality; outcomes; sudden death.

Vytvořeno: 30. 5. 2024 / Upraveno: 6. 6. 2024 / Bc. Luděk Liška